Published in Women's Health Weekly, May 20th, 2004
The first site to enroll patients for this study is Yale-New Haven Hospital, New Haven, Connecticut. The second enrollment site will be announced in June 2004.
Laboratory studies have shown that phenoxodiol has the ability to restore sensitivity to standard chemotherapies in ovarian cancer cells that have been obtained from women whose tumors had previously become resistant to those...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.